ASTRAZENECA PLC News

6-K: Dato-DXd Improved OS in Nonsquamous Lung Cancer

May 28 06:16 ET

AstraZeneca | 6-K: AstraZeneca Plans $1.5 Billion Manufacturing Facility

May 20 06:34 ET

6-K: Supernova Phase Iii Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing Covid-19 in Immunocompromised Patient Population

May 16 06:46 ET

6-K: Transaction by Person Discharging Managerial Responsibilities

May 15 10:10 ET

6-K: AstraZeneca Completes Equity Investment Agreement with Cellectis

May 7 07:34 ET

6-K: Calquence Combination Improved PFS in 1L MCL

May 2 06:53 ET

6-K: Total Voting Rights

May 1 10:29 ET

6-K: Truqap Recommended for EU Breast Cancer Approval

Apr 29 07:22 ET

6-K: Enhertu Improved PFS in HER2-Low and Ultralow

Apr 29 06:52 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 11 13:25 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 11 06:59 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 8 06:17 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 5 06:27 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 2 13:25 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 2 08:49 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 2 07:59 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 25 07:33 ET

ASTRAZENECA | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

Mar 19 17:34 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 19 06:06 ET

ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 14 07:14 ET